Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial

Fig. 1

2-Hydroxybenzylamine (2-HOBA) and primary metabolite (salicylic acid) plasma concentrations after oral administration of 2-HOBA acetate. Plasma concentrations of 2-HOBA (a) and salicylic acid (b) were measured for 8 (first dose) or 24 (last dose) hours after oral administration of 2-HOBA acetate at two dose levels

Back to article page